Source comparison
Best Kisspeptin Dosage Fertility 2026: Protocol Comparison
| Peptide Variant | Administration Route | Effective Dose Range | Dosing Frequency | LH Response Onset | Receptor Saturation Risk | Professional Assessment ||—|—|—|—|—|—|| Kisspeptin-54 | Continuous IV infusion | 0.3–1.0 nmol/kg/hour | Continuous over 2–6 hour
This comparison does not assign a generated winner or score.
- | Peptide Variant | Administration Route | Effective Dose Range | Dosing Frequency | LH Response Onset | Receptor Saturation Risk | Professional Assessment ||—|—|—|—|—|—|| Kisspeptin-54 | Continuous IV infusion | 0.3–1.0 nmol/kg/hour | Continuous over 2–6 hours | 15–30 minutes | High if >1.0 nmol/kg/hour sustained >4 hours | Gold standard for controlled LH pulse studies; requires clinical infrastructure || Kisspeptin-54 | Subcutaneous bolus | Not well-characterised in humans | Experimental only | Variable (30–90 min) | Unknown. Insufficient clinical data | Avoid. Pharmacokinetics poorly understood for this variant/route combination || Kisspeptin-10 | Subcutaneous bolus | 6.4–12.8 nmol/kg | Once daily, cycle-phase timed | 30–60 minutes | Moderate. Daily dosing allows receptor recovery overnight | Practical for research settings without IV capability; dose precision lower || Kisspeptin-10 | Continuous IV infusion | 0.24–0.96 nmol/kg/hour (extrapolated) | Continuous over 2–4 hours | 15–30